Side-by-side · Research reference
LiraglutidevsTesofensine
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedVerified14/45 cited
BPhase 3Draft10/40 cited
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
Tesofensine
SNDRI · Phase 3 obesity candidate
Oral · Once daily morning
01Mechanism of Action
Parameter
Liraglutide
Tesofensine
Primary target
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008
Pathway
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008
Downstream effect
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008
Feedback intact?
Glucose-dependent insulin release preserves physiological feedback
—
Origin
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008
Antibody development
—
—
02Dosage Protocols
Parameter
Liraglutide
Tesofensine
Standard dose (weight, Saxenda)
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
—
Frequency
Once daily, same time each day
Once daily, morning
Titration schedule
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
—
Evidence basis
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
Phase 2b + ongoing Phase 3Astrup 2008
Duration
Indefinite for chronic indication
24 weeks per studied cycle
Reconstitution
Pre-filled commercial pen (no reconstitution)
—
Timing
Any time of day; consistent
Morning to avoid sleep disruption
Lower / starter dose
—
0.125 mg / day
Form
—
Oral capsule
04Side Effects & Safety
Parameter
Liraglutide
Tesofensine
GI symptoms
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
—
Pancreatitis risk
Rare; discontinue if suspected
—
Thyroid C-cell tumours
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
—
Hypoglycemia
Low risk as monotherapy; elevated with sulfonylureas / insulin
—
Heart rate
Modest ↑ resting HR (~2-3 bpm)
—
Pregnancy / OB
Contraindicated
Contraindicated
Insomnia
—
Dose-related; mitigate with morning timing
Dry mouth
—
Common
Nausea
—
Common
Mood changes
—
Anxiety / agitation possible
Cardiovascular events
—
Phase 3 trial monitoring; not yet FDA-cleared
Absolute Contraindications
Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
Tesofensine
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease
- ·Concurrent MAOI use
Relative Contraindications
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
Tesofensine
- ·Hypertension
- ·Anxiety disorder
- ·Insomnia
05Administration Protocol
Parameter
Liraglutide
Tesofensine
1. Reconstitution / device
Commercial pre-filled pen, no reconstitution required.
Oral capsule (investigational; not commercial).
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites.
Swallow whole with water, morning only.
3. Timing
Once daily, same time each day. Take with or without food.
Morning to mitigate insomnia. Do not dose evening.
4. Storage
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
Room temp ≤25 °C, dry place.
5. Needle
Pen-supplied 32G needle.
Monitor BP + HR + mood. Avoid stimulants + MAOIs.